SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ...

Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute uri ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.

CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the following segments: Consumer Products and Specialty Pharmaceutical.

Kenaz Co., Ltd., an independent webtoon intellectual property (IP) holder and studio, said it will accelerate its global growth strategy in 2026 by expanding an integrated webtoon ecosystem that spans ...

The sixth Jiangbeizui New Financial Conference was held in Chongqing's Liangjiang New Area on December 28. Themed "New Finance, New Opportunities: Intelligent Integration for Inclusive and Efficient ...

Applications for the Beefmaster Group’s 2026 academic bursary programme are currently open and will close on 30 December 2025. The bursary targets final-year students in selected agricultural fields ...

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

CapsoVision, Inc. ( ($CV) ) has shared an announcement. On December 29, 2025, CapsoVision, Inc. announced it had submitted a 510(k) application to ...